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Clinical Medicine and Surgery, Federico II UnivAbstract Background and aim: Leukocytes and their subpopulation have been long implicated
in the progression of the syndrome of heart failure (HF), especially heart inﬁltration cells. Previ-
ous reports have suggested that they can predict worse outcome in patients with HF, and can also
affect the function of other cells and myocardial extracellular matrix remodeling process. How-
ever, the lymphocyte-to-monocyte ratio (LMR) and its possible value as prognostic marker have
not been evaluated.
Methods and results: A total of 390 patients with acute HF were recruited and followed for 6
months. Their total blood count with leukocyte differential was obtained. Two groups were
formed according to the endpoints of HF death and optimal cut-off value of LMR, and were
compared. A multivariate Cox-regression model was used to establish the prognostic value with
the endpoints of HF and all-cause mortality. Median age of the patients was 78 years and 48.5%
of themwere men. No major difference was observed between the clinical characteristics of the
two groups. Patients who died of HF had signiﬁcantly higher values of B-type natriuretic pep-
tide and lower values of LMR. Leukocyte and monocyte counts revealed a multivariate-adjusted
risk for both endpoints, whereas relative lymphocyte counts had only signiﬁcant value for all-
cause mortality. The multivariate-adjusted hazard ratios for the 6-month HF and all-cause mor-
tality in patients with LMR values < 2.0 were, respectively, 2.28 (95% CI: 1.25e4.15) and 2.39
(95% CI: 1.39e4.10).
Conclusion: Our results show that, upon discharge from hospital after an episode of acute HF, a
lower value of LMR is independently associated with a higher risk of mortality within 6 months.
ª 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis,
the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery,
Federico II University. Published by Elsevier B.V. All rights reserved.Introduction
Pathophysiology of heart failure (HF) is no longer regarded
as an isolated cardiac entity, but rather an increasinglyorto, Cardiovascular R&D Unit,
Porto, Portugal. Tel.: þ351
.com (N. Silva).
etology, the Italian Society for the Study
ersity. Published by Elsevier B.V. All righmore complex and systemic condition. The types of
prognostic factors associated with the risk of HF morbidity
and mortality have been increasing [1e3], with a special
emphasis on markers associated with inﬂammation, such
as interleukin-6, tumor necrosis factor-a, and C-reactive
protein (CRP) [4e7]. However, regardless of its pathogen-
esis, the major causes of HF progression are still ventric-
ular remodeling and ﬁbrosis. It is shown that mechanisms
of inﬂammation may be evident in this maladaptive pro-
gression of distinct HF etiologies [8]. Heart inﬁltrationof Atherosclerosis, the Italian Society of Human Nutrition, and the Department of
ts reserved.
1034 N. Silva et al.cells, including granulocytes, monocytes, macrophages,
dendritic cells, mast cells, and T- and B-lymphocytes, can
produce and secrete various cytokines, modulating the
inﬂammatory response and affecting the functions of other
cells and myocardial extracellular matrix remodeling
process [9,10].
As both lymphocytes and monocytes play important
roles in HF-related inﬂammation and remodeling/ﬁbrosis,
and considering the heterogeneity of HF, we aim to test if
the LMR is also a useful parameter in discriminating the HF
patients at a higher risk of mortality.
Methods
Study population
We conducted a prospective observational study between
January 2009 and December 2010. In this study, patients
admitted to the department of internal medicine of a
central Portuguese hospital center, with the primary
diagnosis of HF, either worsening or de novo HF, were
included. However, patients with acute coronary syn-
dromes, with symptoms attributable to causes other than
HF, or with no echocardiographic structural or functional
cardiac abnormality were excluded from the study.
An echocardiogram was performed in all eligible pa-
tients within 72 h of admission. A comprehensive echo-
cardiographic assessment was performed using a
multifrequency matrix probe (Vivid S6, GE Healthcare).
The diagnosis of HF was made in accordance with the
guidelines of the European Society of Cardiology [11]. All
HF etiologies were admitted. Both groups of patients with
left ventricular systolic dysfunction (LVSD) and HF with
preserved ejection fraction were included in the study. A
left ventricular ejection fraction (LVEF) of above 50% was
deﬁned as normal systolic fraction. Treatment decisions,
timing of discharge, and discharge medication were at
discretion of the attending physician, and the physicians
were aware of the ongoing study.
Fasting venous blood samples were collected from all
patients between 7 and 8 am on the day of discharge.
Clinical and demographic data were collected, and other
relevant information was obtained by interview upon the
collection of the blood samples. Plasma B-type natriuretic
peptide (BNP) was measured by a chemiluminescent
immunoassay in the Architect i2000 automated analyzer
(Abbott), and serum creatinine and CRP were measured in
the automated clinical chemistry Olympus AU5400
analyzer (Beckman Coulter Inc.). Data on hemoglobin level
and complete blood count (CBC) with leukocyte differen-
tial were obtained in a Sysmex XE-5000 automated blood
counter (Sysmex).
Comorbidities were also recorded for each patient.
Coronary heart disease was veriﬁed with a history of
myocardial infarction, history or electrocardiographic evi-
dence of ischemia, or conﬁrmation of coronary angiog-
raphy. Diabetes mellitus was conﬁrmed with a history of
diabetes or the current prescription of either an oral hy-
poglycemic agent or insulin. Anemia was found to bepresent when the hemoglobin level was <13 and <12 g/dL
in men and women, respectively. Arterial hypertension
was conﬁrmed with the presence of previous diagnosis or
evidence of antihypertensive pharmacological treatment.
Renal dysfunction was suspected when creatinine levels
exceeded 1.5 mg/dL. Alcohol habits of the patients were
determined by clinician evaluation. Estimated glomerular
ﬁltration rate (EGFR) was calculated by the Cock-
crofteGault equation [12].
Patients were followed up for a period of 6 months after
discharge, by means of consultation in the hospitals and/or
telephone contact. The obtained endpoints were HF death,
including worsening congestion because of progressive
pump failure and sudden cardiac death, and all-cause
mortality.
It is worth noting that all patients provided written
informed consent to participate in the study. The study
protocol conformed to the ethical guidelines of the
Declaration of Helsinki, and was approved by the local
ethics committee.
Statistical analysis
Continuous variables are presented as median (inter-
quartile range (IQR)) because of the skewed distribution,
and categorical variables as counts and proportions.
Normality of the variables was determined by the Sha-
piroeWilk test.
Patients were divided according to the endpoint of HF
death and the optimal cut-off value of LMR. This value was
calculated through receiver operating characteristic (ROC)
curves and the Youden index. The Youden index is useful
in the calculation of the maximum vertical distance or
difference between the ROC curve and the diagonal or
chance line, which represents the cut-point that optimizes
the differentiating ability of the biomarker when sensi-
tivity and speciﬁcity are given equal importance. Groups
were formed and compared. A chi-squared test was used
for the comparison of categorical variables, and a Man-
neWhitney test was used for comparing continuous vari-
ables once their distribution was skewed.
A univariate Cox-regression analysis was used for the
assessment of prognostic power of the variables under
study. Variables that were found to be of prognostic sig-
niﬁcance or known to inﬂuence HF prognosis were
included in the developed multivariate models. Variables
with signiﬁcant prognostic power in the multivariate
models were also divided into groups according to their
optimal cut-off values to evaluate their inﬂuence on
stratiﬁcation of our patients.
The KaplaneMeier test was used for estimating the
survival function of patients in the 6-month follow-up
with both outcomes in study, and according to the cut-off
value calculated by the Youden index.
It was considered that p Z 0.05 is statistically signiﬁ-
cant with a conﬁdence interval of 95%.
Data were stored and analyzed using software packages
such as SPSS Statistics 20.0 (SPSS Inc., Chicago, IL, USA) and
MedCalc 14.8.1 (MedCalc Software bvba, Ostend, Belgium).
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This study included 390 patients discharged after hospi-
talization due to an acute episode of HF. The median age of
the patients was 78 years (IQR: 70e84), and 48.5% of them
were men. Ischemic HF etiology was found in 35.4% of the
patients, 58.2% had systolic HF, and 19.2% were discharged
with a New York Heart Association (NYHA) class of III or IV.
Diabetes mellitus and anemia were comorbidities in 43.8%
and 42.8% of the patients, respectively. Arterial hyperten-
sion affected 76.9% of the patients, and 22.8% suffered from
renal dysfunction. In addition, approximately 50% of the
patients were drinkers, and 36.4% were current or ex-
smokers. Characteristics, comorbidities, and results ofTable 1 Patients’ demographics, clinical and laboratory characteristics, an
to HF and survivors at 6-month follow-up.
All patients
(n Z 390)
Clinical characteristics
Age (years), median (IQR) 78 (70e84)
Male sex, n (%) 189 (48.5)
Ischemic etiology of HF, n (%) 138 (35.4)
Preserved LVSF, n (%) 163 (41.8)
NYHA class at discharge
(III & IV vs. I & II), n (%)
75 (19.2)
Comorbidities
Diabetes mellitus, n (%) 171 (43.8)
Anemia history, n (%) 167 (42.8)
Chronic arterial hypertension, n (%) 300 (76.9)
Chronic renal dysfunction, n (%) 89 (22.8)
Smoking habits, n (%)
Current smoker/ex-smoker 31/111 (7.9/28.5)
Alcohol habits, n (%) 179 (45.9)
Laboratory at discharge
Hemoglobin (g/dL), median (IQR) 12.0 (10.8e13.5)
GFR (mL/min), median (IQR) 39.2 (28.7e51.9)
BNP (pg/mL), median (IQR) 727.1
(309.0e1353.9)
CRP (mg/L), median (IQR) 12.3 (6.3e25.3)
Leukocytes
Count (cells/mL), median (IQR) 7215 (5808e8633)
Monocytes
Count (cells/mL), median (IQR) 580 (460e770)
Relative count (%), median (IQR) 8.5 (6.8e10.3)
Lymphocytes
Count (cells/mL), median (IQR) 1410 (1060e1860)
Relative count (%), median (IQR) 20.6 (15.3e25.6)
Lymphocyte-to-monocyte ratio,
median (IQR)
2.4 (1.7e3.2)
Discharge medication
ACEi, n (%) 265 (67.9)
ARA, n (%) 52 (13.3)
Spironolactone, n (%) 102 (26.2)
Beta-blocker, n (%) 310 (79.5)
Nitrates, n (%) 102 (26.2)
Statins, n (%) 250 (64.1)
Diuretic, n (%) 367 (94.1)
IQR: interquartile range; HF: heart failure; LVSF: left ventricular systolic fun
ﬁltration rate; BNP: B-type natriuretic peptide; CRP: C-reactive protein;
receptor antagonist; LMR: lymphocyte-to-monocyte ratio; p value signiﬁclaboratory assessment of the patients are shown in Table 1.
The patients were followed up for 6 months after
discharge, during which 51 patients died due to HF among
the total 66 deaths. Table 1 also presents the classiﬁcation
of patients based on the endpoint of HF. Patients who died
because of HF had signiﬁcantly higher values of BNP and
monocyte counts, whereas hemoglobin levels and relative
counts of lymphocytes were signiﬁcantly reduced. They
also presented signiﬁcantly lower LMR values, and were
also less prompt to have chronic arterial hypertension.
Table 2 presents the predictors of 6-month HF mortality
and all-cause mortality for our group of patients in a
univariate approach. The predictors of HF death were the
presence of ischemic etiology of HF, a higher NYHA class, ad discharge medication; Comparison between patients who died due
HF death
(n Z 51)
Non-HF death/Survivors
(n Z 339)
p
Value
78 (72e86) 77 (69e83) 0.101
29 (56.9) 160 (47.2) 0.205
23 (45.1) 115 (33.9) 0.102
16 (31.4) 147 (43.4) 0.110
17 (33.3) 58 (17.1) 0.005
20 (39.2) 151 (44.5) 0.464
26 (51.0) 141 (41.6) 0.244
31 (60.8) 269 (79.4) 0.007
15 (29.4) 74 (21.8) 0.268
0/18 (0.0/35.3) 31/93 (9.1/27.4) 0.059
22 (43.1) 157 (46.3) 0.718
11.6 (10.4e12.4) 12.1 (10.9e13.7) 0.018
33.4 (25.6e47.4) 40.2 (29.6e53.3) 0.064
1829.6
(1080.2e2656.0)
602.0
(263.2e1208.4)
<0.000
15.7 (9.2e30.6) 11.4 (6.0e24.9) 0.059
7590 (6030e9800) 7155 (5783e8573) 0.164
670 (520e920) 570 (448e760) 0.012
8.7 (7.1e11.0) 8.5 (6.7e10.3) 0.314
1300 (1000e1790) 1420 (1070e1860) 0.251
18.0 (12.4e23.1) 21.2 (15.7e26.1) 0.015
2.0 (1.4e2.6) 2.4 (1.8e3.3) 0.001
26 (51.0) 239 (70.5) 0.015
5 (9.8) 47 (13.9) 0.478
11 (21.6) 91 (26.8) 0.506
31 (60.8) 279 (82.3) 0.002
12 (23.5) 90 (26.5) 0.708
29 (56.9) 221 (65.2) 0.360
47 (92.2) 320 (94.4) 0.897
ction; NYHA: New York Heart Association; GFR: estimated glomerular
ACEi: angiotensin-converting enzyme inhibitor; ARA: angiotensin II
ance lower than 0.05 (95% CI).
1036 N. Silva et al.history of arterial hypertension, a higher BNP, lower he-
moglobin levels, and lower GFR values upon discharge. The
prescription of angiotensin-converting enzyme inhibitor
and beta-blockers showed to have a signiﬁcant protective
effect in both models. Besides the predictors indicated for
HF death, aging, the presence of chronic renal dysfunction,
and higher CRP values were also found to be signiﬁcant
indicators of all-cause death. Higher leukocyte and
monocyte counts showed a univariate signiﬁcant prog-
nostic value for HF and all-cause death. The same univar-
iate value was observed for lower relative lymphocyte
counts, as well as lower values of LMR.
For the variables with prognostic statistical value in a
univariate approach, the optimal cut-off values based on
the ROC curves and Youden index were determined. The
cut-off values for both endpoints are presented in Table 3.
For monocyte counts and LMR, the cut-off values were theTable 2 Univariate Cox-regression between patients’ characteristics and
failure episode.
HF death (n Z
HR (95% CI)
Clinical characteristics, all patients (n Z 390)
Age (per year) 1.00 (1.00e1.01
Male sex 1.42 (0.81e2.48
Ischemic etiology of HF 1.27 (1.05e1.54
Preserved LVSF 1.54 (0.85e2.79
NYHA class at discharge (III & IV vs. I & II) 1.33 (1.09e1.62
Comorbidities
Diabetes mellitus 0.90 (0.68e1.19
Anemia history 0.98 (0.73e1.31
Chronic arterial hypertension 0.46 (0.26e0.82
Chronic renal dysfunction 1.10 (0.89e1.36
Smoking habits 1.13 (0.92e1.37
Alcohol habits 0.89 (0.51e1.55
Laboratory at discharge
Hemoglobin (per g/dL) 0.84 (0.73e0.98
GFR (per mL/min) 0.98 (0.97e1.00
BNP (per 100 pg/mL) 1.02 (1.01e1.03
CRP (per 10 mg/L) 1.08 (0.99e1.16
Leukocytes
Count (per 1000 cells/mL) 1.08 (1.02e1.15
Monocytes
Count (per 100 cells/mL) 1.13 (1.04e1.22
Relative count (per %) 1.04 (0.95e1.14
Lymphocytes
Count (per 100 cells/mL) 0.99 (0.95e1.03
Relative count (per %) 0.96 (0.92e0.99
Lymphocyte-to-monocyte ratio (per unit) 0.69 (0.52e0.91
Discharge medication
ACEi 0.51 (0.29e0.89
ARA 0.70 (0.28e1.77
Spironolactone 0.77 (0.39e1.50
Beta-blocker 0.40 (0.22e0.71
Nitrates 0.83 (0.49e1.42
Statins 0.77 (0.43e1.35
Diuretic 0.85 (0.41e1.75
HR: hazard ratio; IQR: interquartile range; HF: heart failure; LVSF: left ve
NYHA: New York Heart Association; GFR: estimated glomerular ﬁltration
angiotensin-converting enzyme inhibitor; ARA: angiotensin II receptor ansame for both the endpoints, 570 and 2.0 cells/mL,
respectively. However, the cut-off values were slightly
different between HF death and all-cause death for leu-
kocytes (10,970 and 10,400 cells/mL) and relative lym-
phocytes (17.6% and 17.8%).
In the multivariate-adjusted models for predicting
outcome, all the variables tested in continuous analysis,
excluding relative lymphocytes for HF death, were inde-
pendently signiﬁcant of other prognostic predictors. When
divided by the cut-off value, all variables maintained a
signiﬁcantly independent prognostic value. However, only
relative lymphocytes for all-cause death (0.96, 95% CI:
0.93e1.00 vs. 1.86, 95% CI: 1.09e3.18) and LMR for both
endpoints had a higher hazard ratio (HR) than the one in
the continuous analysis. In fact, when divided by the cut-
off value, LMR revealed signiﬁcantly adjusted HRs of 2.28
(95% CI: 1.25e4.15) and 2.39 (95% CI: 1.39e4.10), for 6-6-month heart failure and all-cause mortality, after an acute heart
51) All-cause death (n Z 66)
p Value HR (95% CI) p Value
) 0.072 1.03 (1.00e1.05) 0.033
) 0.211 1.08 (0.67e1.75) 0.747
) 0.012 1.24 (1.03e1.49) 0.020
) 0.154 0.96 (0.59e1.56) 0.862
) 0.004 1.31 (1.10e1.56) 0.002
) 0.446 0.84 (0.66e1.08) 0.182
) 0.891 1.11 (0.94e1.31) 0.230
) 0.008 0.47 (0.28e0.79) 0.004
) 0.386 1.23 (1.08e1.39) 0.002
) 0.240 1.07 (0.88e1.30) 0.519
) 0.673 0.75 (0.46e1.24) 0.262
) 0.023 0.82 (0.72e0.94) 0.003
) 0.041 0.98 (0.97e1.00) 0.011
) <0.000 1.02 (1.01e1.02) <0.000
) 0.069 1.08 (1.02e1.16) 0.014
) 0.006 1.08 (1.02e1.14) 0.006
) 0.003 1.11 (1.03e1.19) 0.005
) 0.402 1.03 (0.95e1.12) 0.497
) 0.545 0.98 (0.94e1.02) 0.260
) 0.020 0.95 (0.92e0.99) 0.004
) 0.010 0.68 (0.53e0.88) 0.003
) 0.018 0.54 (0.33e0.88) 0.014
) 0.452 0.76 (0.34e1.66) 0.484
) 0.443 0.81 (0.46e1.45) 0.479
) 0.002 0.51 (0.30e0.86) 0.012
) 0.506 0.86 (0.55e1.34) 0.509
) 0.358 0.80 (0.48e1.33) 0.389
) 0.655 0.89 (0.51e1.55) 0.691
ntricular systolic function; LVSD: left ventricular systolic dysfunction;
rate; BNP: B-type natriuretic peptide; CRP: C-reactive protein; ACEi:
tagonist; p value signiﬁcance lower than 0.05 (95% CI).
Table 3 Values of area under the ROC curve (AUC), sensitivity, and speciﬁcity for the optimal cut-off for the Youden index.
HF death All-cause death
Cut-off Sensitivity
(%)
Speciﬁcity
(%)
AUC Cut-off Sensitivity
(%)
Speciﬁcity
(%)
AUC
Leukocytes count (cells/mL) >10,970 22 92 0.560 >10,400 24 89 0.564
Monocytes count (cells/mL) >570 69 52 0.609 >570 64 52 0.587
Lymphocytes relative count (%) 17.6 49 69 0.606 17.8 50 69 0.614
Lymphocyte-to-monocyte ratio 2.0 61 66 0.643 2.0 59 67 0.646
HF: heart failure; AUC: area under the curve.
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multivariate-adjusted models and HR of 6-month HF and
all-cause mortality are shown in Table 4.
Estimates clearly revealed a signiﬁcantly higher risk of
death, by HF or other causes, in patients with lower values
of LMR upon discharge. Fig. 1 shows the survival curves
estimator for the 6-month period, based on the LMR cut-
off values (1.7) for HF and all-cause death.
Although no major difference was noted between the
clinical characteristics of patient groups, patients with
lower LMR values showed signiﬁcantly higher values of
BNP and CRP. They also showed signiﬁcantly higher values
of leukocyte and monocyte counts, but lymphocyte counts
were signiﬁcantly reduced. These patients also exhibited to
be more prompt to have chronic renal dysfunction and
lower levels of hemoglobin at discharge. Of the 51 patients
who died because of HF, 22 had lower LMR values (Table 5).
Discussion
We report that upon discharge from an acute HF episode,
LMR < 2.0 is a strong predictor of unfavorable outcome.
Even after adjustment for commonly predictive risk factorsTable 4 Multivariate Cox-regression model on 6-month HF death and all
HF deatha
HR (95% CI)
Leukocytes
Count (per 1000 cells/mL) 1.09 (1.02e1
Count (cut-off value) 0.37 (0.18e0
Monocytes
Count (per 100 cells/mL) 1.12 (1.03e1
Count (cut-off value) 0.48 (0.26e0
Lymphocytes
Relative count (per %) 0.96 (0.93e1
Relative count (cut-off value) e
Lymphocyte-to-monocyte ratio (per unit) 0.72 (0.53e0
Lymphocyte-to-monocyte ratio (cut-off value) 2.28 (1.25e4
HR: hazard ratio; HF: heart failure; p value signiﬁcance lower than 0.05 (
a Model adjusted for: Ischemic etiology of heart failure; New York Hea
hypertension; Hemoglobin (per g/dL); Estimated glomerular ﬁltration rate
enzyme inhibitor; Beta-blocker medication.
b Model adjusted for: Age (per year); Ischemic etiology of heart failure; N
arterial hypertension; Chronic renal dysfunction; Hemoglobin (per g/dL);
100 pg/mL); C-reactive protein (per 10 mg/L); Angiotensin-converting enzand confounders, a lower LMR represented approximately
2.3-fold increased risk of 6-month HF and all-cause death.
To our knowledge, this is the ﬁrst study that describes this
association in HF patients. This is even more relevant as
one of the currently identiﬁed limitations in the handling
of HF patients relates to the prediction of disease evolution
and severity.
The leukocyte differential is easily assessable, and it
represents a potentially and weakly explored tool in HF
prognostics and management. An association between
high leukocyte count and risk factors related to the
development of HF, such as coronary heart disease,
myocardial infarction, and stroke, has been observed
[13e15]. Other comorbidities found in HF patients, such as
diabetes [16] and weight gain [17], have also been asso-
ciated with high leukocyte count. In middle-aged men, an
association with increased long-term incidence of HF
hospitalizations was also described [18]. Therefore, the
relationship between high leukocyte count and HF can be
mediated by the incidence of risk factors commonly
associated with this condition. In fact, high leukocyte
count can be an important earlier risk marker for many
individuals. Nevertheless, in our group of patients,-cause mortality, after an acute HF episode.
All-cause deathb
p Value HR (95% CI) p Value
.15) 0.006 1.08 (1.02e1.15) 0.009
.79) 0.009 0.43 (0.22e0.83) 0.012
.21) 0.009 1.12 (1.03e1.21) 0.005
.89) 0.021 0.47 (0.28e0.84) 0.011
.00) 0.063 0.96 (0.93e1.00) 0.044
1.86 (1.09e3.18) 0.024
.98) 0.038 0.72 (0.55e0.95) 0.019
.15) 0.007 2.39 (1.39e4.10) 0.002
95% CI).
rt Association class at discharge (III & IV vs. I & II); Chronic arterial
; B-type natriuretic peptide (per 100 pg/mL); Angiotensin-converting
ew York Heart Association class at discharge (III & IV vs. I & II); Chronic
Estimated glomerular ﬁltration rate; B-type natriuretic peptide (per
yme inhibitor; Beta-blocker medication.
Figure 1 KaplaneMeier survival curves according to lymphocyte-to-monocyte ratio cut-off values of 2.0. Left: heart failure death endpoint; Right:
all-cause death endpoint. Patients with lower values of lymphocyte-to-monocyte ratio had a higher 6-month risk of death for both endpoints after
an acute heart failure episode. LMR: lymphocyte-to-monocyte ratio.
1038 N. Silva et al.leukocyte count showed a signiﬁcant prognostic value for
both endpoints, independent of other common risk factors
such as ischemic etiology and history of hypertension. For
HF and all-cause death, the HRs were 1.09 and 1.08,
respectively, for each 1000 cells/mL increase.
Individual leukocyte subpopulations represent single
elements of the leukocyte differential and immunological
processes. In patients with HF, lower relative lymphocyte
counts have been associated with worse outcomes
[19e22]. It is also evident from our study that lower
relative lymphocyte counts were associated with all-cause
death and a trend to predict HF death. However, when
divided by quartiles, these counts did not retain a signiﬁ-
cant predictive value. Availability of limited data regarding
monocytes shows conﬂicting results. In patients with an
existing diagnosis of HF, increased monocyte count was
found to be associated with HF and unfavorable outcomes
[23,24]. However, the Atherosclerosis Risk in Communities
(ARIC) study found no association between monocyte
count and HF [15]. Our data corroborates the ﬁndings
associated with unfavorable outcomes, since in our group
of patients, a higher monocyte count (>770 cells/mL)
independently indicated a higher risk of HF and all-cause
death.
The LMR is determined from the counts of lymphocytes
and monocytes, two different cells included in the leuko-
cyte differential. Relative lymphopenia reﬂects a physio-
logic stress response, whereas monocytosis reﬂects a
chronic systemic inﬂammation. It has been found recently
that a low LMR is associated with a high mortality in pa-
tients with malignant hematologic disorders [25e27] and
atherosclerotic disease [28]. In recent years, activation of
the immune system and inﬂammation have been well
characterized in HF, being now certain that they play
important roles in this condition [29e32]. It has also been
shown that lymphocytes and monocytes can be activated
by proinﬂammatory cytokines [33e35]. This activation
converts the cells into potential sources ofproinﬂammatory cytokines that lead to further activation
of these cells, contributing to the systemic inﬂammation in
HF patients. High circulating levels of proinﬂammatory
cytokines may have several adverse effects in patients with
HF, including myocardial remodeling, promotion of cardiac
arrhythmia, and negative inotropy [36,37]. The most
acceptable hypothesis for mediators that can activate this
response, especially in acute episodes of HF, is bacterial
endotoxin translocation due to intestinal bacterial prolif-
eration. Several studies indicate that during repetitive
episodes of decompensation, particularly when associated
with severe systemic congestion, bacterial endotoxin
translocation may occur from the gut into circulation. This
translocation would activate lymphocytes and monocytes
with the consequent release of proinﬂammatory cytokines
[38e41]. This hypothesis clariﬁes our results in LMR. The
approximately 2.5-fold higher risk of death found in our
study may reﬂect the endotoxin translocation and immune
activation of lymphocytes and monocytes. This activation
will result in higher counts of these cells and subsequent
lower LMR values, representative of a higher risk group of
patients.
The main objective of this study was to evaluate if LMR
could successfully discriminate patients at a higher risk of
death, independently of standard risk predictors. To our
knowledge, this is the ﬁrst study that strongly establishes a
signiﬁcant role of LMR as a predictor marker of mortality
in an adjusted survival model.
In order to clarify whether these low values of LMR are
directly involved in the pathogenesis of HF or whether
they are just a marker of disease severity, further research
is needed to be conducted. The limitation of this study is
its inability to reveal the exact pathophysiologic mecha-
nisms hidden behind LMR. Alongside with this limitation,
we also acknowledge that this is a single-center study with
all the well-known bias and inherent confounding. For this
reason, an external validation by an independent cohort
must be the ﬁrst step in investigations to safely establish
Table 5 Patients’ demographics, clinical and laboratory characteristics, and discharge medication according to the LMR cut-off value.
Low LMR (n Z 95) High LMR (n Z 295) p Value
Clinical characteristics
Age (years), median (IQR) 78 (72e84) 78 (69e84) 0.358
Male sex, n (%) 51 (53.7) 137 (46.6) 0.230
Ischemic etiology of HF, n (%) 36 (37.9) 102 (34.7) 0.630
Preserved LVSF, n (%) 42 (44.2) 121 (41.2) 0.650
NYHA class at discharge (III & IV vs. I & II), n (%) 22 (23.2) 53 (18.0) 0.230
Comorbidities
Diabetes mellitus, n (%) 43 (45.3) 128 (43.5) 0.768
Anemia history, n (%) 46 (48.4) 121 (41.2) 0.500
Chronic arterial hypertension, n (%) 74 (77.9) 225 (76.5) 0.962
Chronic renal dysfunction, n (%) 29 (30.5) 60 (20.4) 0.067
Smoking habits, n (%)
Current smoker/ex-smoker 11/30 (11.6/31.6) 20/80 (6.8/27.2) 0.235
Alcohol habits, n (%) 49 (51.6) 129 (43.9) 0.218
Laboratory at discharge
Hemoglobin (g/dL), median (IQR) 11.8 (10.9e12.7) 12.1 (10.8e13.7) 0.077
GFR (mL/min), median (IQR) 34.4 (25.8e50.7) 40.0 (29.7e52.4) 0.198
BNP (pg/mL), median (IQR) 871.6 (451.2e1633.9) 657.9 (262.9e1307.3) 0.007
CRP (mg/L), median (IQR) 15.5 (8.2e36.5) 11.1 (5.5e24.6) 0.005
Leukocytes
Count (cells/mL), median (IQR) 7690 (6030e9720) 7085 (5785e8485) 0.049
Monocytes
Count (cells/mL), median (IQR) 780 (590e1010) 540 (430e700) <0.000
Relative count (%), median (IQR) 10.6 (8.1e12.4) 8.0 (6.6e9.6) <0.000
Lymphocytes
Count (cells/mL), median (IQR) 1010 (720e1330) 1580 (1198e2043) <0.000
Relative count (%), median (IQR) 13.6 (9.5e17.8) 22.8 (18.8e27.3) <0.000
Lymphocyte-to-monocyte ratio, median (IQR) 1.4 (1.1e1.6) 2.7 (2.2e3.6) <0.000
Discharge medication
ACEi, n (%) 59 (62.1) 205 (69.7) 0.141
ARA, n (%) 11 (11.6) 41 (13.9) 0.541
Spironolactone, n (%) 22 (23.2) 79 (26.9) 0.453
Beta-blocker, n (%) 70 (73.7) 239 (81.3) 0.085
Nitrates, n (%) 26 (27.4) 76 (25.9) 0.769
Statins, n (%) 65 (68.4) 185 (62.9) 0.282
Diuretic, n (%) 89 (93.7) 277 (94.2) 0.698
HF death 22 (23.3) 29 (9.9) 0.001
All-cause death 29 (30.5) 37 (12.6) <0.000
IQR: interquartile range; HF: Heart failure; LVSF: Left ventricular systolic function; NYHA: New York Heart Association; GFR: Estimated
glomerular ﬁltration rate; BNP: B-type natriuretic peptide; CRP: C-reactive protein; ACEi: Angiotensin-converting enzyme inhibitor; ARA:
Angiotensin II receptor antagonist; LMR: Lymphocyte-to-monocyte ratio; p value signiﬁcance lower than 0.05 (95% CI).
Lymphocyte-to-monocyte ratio in heart failure 1039and conﬁrm the potential use of this ratio in predicting HF
outcomes. Nevertheless, our main goal was to demonstrate
that LMR is an easily obtained, widely available, and
inexpensive tool that can be used in the risk stratiﬁcation
between HF patients with high and low risk of death, in
addition to the traditionally used markers.Conclusion
Our results show that upon discharge from hospital after
an episode of acute HF, LMR < 2.0 is associated with an
approximately 2.3-fold higher risk of 6-month HF and all-
cause mortality. Our results suggest that this ratio may
have a role in the identiﬁcation of patients with increased
risk of mortality.Acknowledgment
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